Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
Me-(S,R,S)-AHPC-CO-C5-N3 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound combines a VHL ligand with a specialized linker, facilitating the synthesis of PROTACs. Its utility in developing PROTACs, such as PROTAC CG167, underscores its relevance in chemical biology and therapeutic research focused on protein regulation. -
E3 Ligase Ligand-Linker Conjugates
Phenyl-glutarimide 4'-oxyacetic-amide-C5-amide-Boc is a specialized E3 ligase ligand-linker conjugate designed for use in the synthesis of targeted protein degradation compounds, such as PROTAC SJ995973. This reagent facilitates the development of bifunctional molecules that can selectively induce the ubiquitination of target proteins, thereby enhancing the efficiency of protein degradation research. Its utility in proteolysis-targeting chimera (PROTAC) studies makes it a valuable tool for exploring new therapeutic strategies in various biological systems. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-Linker Conjugate 188 functions as a ligand-linker conjugate specifically for E3 ligases. This compound is utilized in the synthesis of AZ'3137, facilitating the study of targeted protein degradation and cellular signaling pathways. Its distinctive design enables researchers to explore the roles of E3 ligases in various biological processes and drug development applications. -
E3 Ligase Ligand-Linker Conjugate
Pom-8PEG is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. It features a cereblon (CRBN) ligand that facilitates interaction with the E3 ubiquitin ligase, connected via an 8-unit polyethylene glycol (PEG) linker. This compound serves as a crucial component in the synthesis of Proteolysis Targeting Chimeras (PROTACs), enabling specific degradation of target proteins, including potential applications in the development of IDO1 PROTAC degraders. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG4-C2-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the Pomalidomide-derived cereblon ligand with a four-unit polyethylene glycol (PEG) linker. This compound serves as a critical component in PROTAC (proteolysis-targeting chimeras) technology, facilitating targeted protein degradation. Its design enables efficient recruitment of E3 ubiquitin ligases, enhancing the regulation of protein levels in research applications focused on protein homeostasis and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 15 is a novel conjugate designed for use with E3 ubiquitin ligases. This reagent facilitates the synthesis of complete PROteolysis TArgeting Chimeras (PROTACs), enabling targeted protein degradation. Its application is crucial for researchers investigating protein dynamics and therapeutics aimed at modulating cellular pathways through ubiquitin-mediated degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C2-2-azaspiro[3.3]heptane is a conjugate designed for targeting E3 ubiquitin ligases and serves as a linker component in the development of bifunctional degradation technologies. This compound plays a crucial role in the synthesis of KT-413, facilitating selective protein degradation for research applications in cancer and other diseases. Its unique structure enhances ligand-receptor interactions, offering valuable insights into E3 ligase biology and therapeutic targeting. -
HyT and Linker Conjugates
2-(2-Aminoethoxy)ethyl 2-(adamantan-1-yl) acetate serves as a hybrid compound that integrates a hydrophobic group with a linker. This reagent is essential for the synthesis of SARD279, a compound that can be utilized in various research applications including cell signaling and protein interaction studies. Its unique structure facilitates the development of targeted therapy strategies in chemical biology. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-PEG-NHCO-C2-COOH targets cereblon (CRBN) and functions as an E3 ligase ligand-linker conjugate. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs) for the selective degradation of proteins, specifically enabling the development of the ASK1 degrader dASK1. It is valuable for research in targeted protein degradation and E3 ligase modulation. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-phenylacetic acid is an E3 Ligase Ligand-Linker Conjugate designed for targeted protein degradation applications. This compound serves as a critical building block for the synthesis of PROTAC SMARCA2/4-degrader-15, facilitating the ubiquitination and degradation of specific target proteins. Its utility in PROTAC development underscores its significance in advancing therapeutic strategies in cellular regulation and protein homeostasis studies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. It combines a VH032-derived VHL ligand with a linker specifically for the estrogen-related receptor α (ERRα) PROTAC system. This compound facilitates the formation of complex structures that promote the ubiquitination and subsequent degradation of ERRα, thereby enabling in-depth studies on its biological functions and potential therapeutic interventions. -
Ligands for E3 Ligase
VH032-C6-NH-Boc is a Boc-modified ligand that targets the von Hippel-Lindau (VHL) E3 ligase, facilitating the recruitment of VHL proteins. Under acidic conditions, it readily deprotection occurs, allowing its direct utilization in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound serves as a crucial intermediate in developing PROTACs utilizing VHL ligands, thereby advancing research in targeted protein degradation. -
E3 Ligand
(S,R,S)-AHPC-O-PEG1-propargyl is an E3 ligand utilized for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions with azide-containing molecules. Its primary applications include facilitating targeted protein degradation studies and drug discovery efforts in chemical biology. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 201 is a synthesized compound designed to target E3 ligases, facilitating the development of Proteolysis Targeting Chimeras (PROTACs). This reagent is instrumental in the advancement of targeted protein degradation strategies and can be utilized for the synthesis of various PROTACs, including PROTAC ER Degrader-3. Its application in research supports efforts to modulate protein levels and explore therapeutic pathways in cellular contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidine is an E3 Ligase Ligand-Linker Conjugate that facilitates the formation of targeted protein degradation systems. This compound serves as a crucial component in the synthesis of SMART1, enabling precise modulation of protein levels within cellular contexts. Its applications extend to enhancing understanding of protein function and therapeutic development in disease models. -
E3 Ligase Ligand-Linker Conjugates
N-Boc-SBP-0636457-O-C3-COOH is a synthesized E3 ligase ligand-linker conjugate, designed to facilitate targeted protein degradation via PROTAC technology. This compound incorporates an IAP ligand and a linker, enabling the development of Bcl-xL degraders. It is particularly useful in studies aimed at elucidating the role of Bcl-xL in cellular processes and therapeutic applications in cancer research. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 180 is designed to target E3 ubiquitin ligases, facilitating the development of targeted protein degradation strategies. This conjugate enables the synthesis of novel compounds, such as KI-CDK9d-32, and serves as a valuable tool in research focused on modulating protein levels and exploring ubiquitin-proteasome pathways. Its applications extend to investigations in cancer biology, where E3 ligases play critical roles in regulating protein stability and function. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 142 is a specialized conjugate designed to target E3 ubiquitin ligases through its ligand-linker structure. This reagent plays a critical role in the development of protein degradation technologies, facilitating the synthesis of CFT8634, a compound of interest in therapeutic research. Its application promotes efficient protein modulation, which is essential for exploring cellular pathways and developing novel drug strategies in the field of cancer therapy and beyond. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-5-F-6-azetidin-MeOH is an E3 ligase ligand-linker conjugate, specifically designed for the synthesis of PROTAC FLT3/CHK1 Degrader-1. This compound effectively targets and degrades FLT3 and CHK1, demonstrating significant anti-tumor activity. It serves as a valuable tool in drug development research, facilitating insights into targeted protein degradation mechanisms in cancer therapy. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-hex-5-ynoic acid is an E3 ligase ligand-linker conjugate designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound serves as a critical component in the development of targeted protein degradation strategies, exemplified by its role in the PROTAC cGAS degrader-1. Its utility in drug discovery and development research positions it as a valuable tool for investigating protein modulation and pathway exploration. -
VHL Ligand
VH 032 amide-alkylC6-acid is a ligand specifically targeting the von Hippel-Lindau (VHL) protein. As an analog of VH032, it plays a pivotal role in recruiting VHL for various biological processes. This compound is instrumental in the synthesis of PROTACs, facilitating targeted protein degradation for research applications in cancer biology and cellular regulation. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 127 is a targeted E3 ligase ligand-linker conjugate designed for use in the development of PROTAC (Proteolysis Targeting Chimeras) techniques. This compound facilitates the synthesis of the BRM/BRG1 degrader-3, enabling researchers to study targeted protein degradation pathways and E3 ligase interactions. Its application supports advancements in therapeutic strategies for diseases driven by aberrant protein expression. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-C3-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating the VH032-based VHL ligand and a linker utilized in PROTAC (proteolysis-targeting chimera) technology. This compound serves as a critical building block in the synthesis of various PROTACs, including UNC6852, which is a bivalent chemical degrader specifically targeting EED. (S,R,S)-AHPC-C3-NH2 dihydrochloride facilitates investigations into targeted protein degradation, offering valuable insights into protein regulation and potential therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-PEG4-OTs is an E3 ligase ligand-linker conjugate designed to target cereblon (CRBN). This compound features a Thalidomide-derived ligand integrated with a four-unit polyethylene glycol (PEG) linker, facilitating the development of proteolysis-targeting chimeras (PROTACs). It is particularly useful in research focused on targeted protein degradation and therapeutic applications involving immune responses. -
Ligands for E3 Ligase
(S,R,S)-AHPC-CO-C9-NH2 is a Von Hippel-Lindau (VHL) ligand that serves as a crucial building block for the synthesis of E3 ligase ligands utilized in the development of PROTACs (Proteolysis Targeting Chimeras). This compound enhances the understanding of protein degradation pathways and enables targeted protein modulation, making it a valuable tool for researchers investigating targeted therapies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-pyrrolidine-C-azaspiro is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation through the ubiquitin-proteasome system. This compound is instrumental in the development of novel therapeutic agents by enabling the synthesis of specific degradation probes, such as CW-3308. Its application in chemical biology extends to enhancing the understanding of protein dynamics and function in cellular processes. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C11-Br is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived CRBN ligand with a specialized linker utilized in PROTAC technology. This compound enables the targeted degradation of proteins by facilitating the formation of PROTAC EZH2 Degrader-23, thereby enhancing research into targeted protein degradation mechanisms. Its application in drug discovery and development provides a valuable tool for studying protein regulation and therapeutic interventions. -
E3 Ubiquitin Ligase Ligands and Linkers for PROTACs
E3 Ligase Ligand-linker Conjugate 139 is designed to bind to E3 ubiquitin ligases, serving as a critical component in the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates ubiquitination and subsequent degradation of target proteins, making it a valuable tool for cancer research and therapeutic applications. Its unique properties enable efficient disruption of protein homeostasis, offering insights into cellular pathways and potential treatment strategies in oncology. -
E3 Ligase Ligand-Linker Conjugates
5-Aminothalidomide-C9-Boc is a ligase ligand-linker conjugate targeting E3 ligases. It serves as a critical component in the synthesis of the PROTAC TRIB2 degrader-1, facilitating targeted protein degradation. This compound is essential for research applications involving small molecule-induced protein degradation and targeted therapy development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG3-NH2 is an E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from Pomalidomide, combined with a PEG3 linker. This compound facilitates targeted protein degradation via PROTAC technology, enabling selective modulation of protein levels in cellular systems. It is valuable for research applications focused on understanding protein homeostasis and exploring therapeutic strategies in diseases involving dysregulated protein expression. -
E3 Ligase Ligand-linker Conjugate
Pomalidomide-NH-C13-OH is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC PI3Kα degrader-1, enabling the selective degradation of the PI3Kα protein. Its effective engagement with E3 ligases makes it a valuable tool for research in targeted therapies and the modulation of cellular protein levels. -
E3 Ubiquitinase Ligand-Linker Conjugate
Pomalidomide 4'-alkylC8-acid is an E3 ubiquitin ligase ligand-linker conjugate featuring Pomalidomide, a third-generation immunomodulator. This compound functions as a molecular glue, binding to the E3 ligase cereblon and facilitating the degradation of the essential Ikaros transcription factor. It is valuable for research applications related to targeted protein degradation and understanding the regulatory mechanisms of immune response. -
Ligands for E3 Ligase
Pomalidomide-C11-NH2 is a Pomalidomide derivative that functions as a ligand for the E3 ligase cereblon (CRBN). This compound facilitates the recruitment of CRBN protein, enabling targeted protein degradation applications through PROTAC technology. Its utility in the development of targeted therapeutics offers significant potential for advancing cancer research and treatment strategies. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-PEG3-azide is an E3 ligase ligand-linker conjugate that facilitates the synthesis of proteolysis-targeting chimeras (PROTACs). This compound can be employed in studies aiming to degrade specific target proteins, including 11β-HSD1, thus providing insights into protein regulation and turnover mechanisms. It serves as a valuable tool for researchers investigating targeted protein degradation strategies in therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH is an E3 ligase ligand-linker conjugate featuring a VHL ligand. This compound is utilized in PROTAC (Proteolysis Targeting Chimeras) technology, which enables targeted protein degradation. Its design facilitates selective degradation of specific proteins, making it a valuable tool for studying protein function and developing therapeutic strategies in various diseases. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-C9-NH2 hydrochloride is a von Hippel-Lindau (VHL) amino building block that serves as a crucial component for the synthesis of E3 ligase ligands. This compound functions as a linker in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation. Its key biological activity supports research in cellular signaling, protein homeostasis, and therapeutic development for various diseases. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-5-C7-NH2 serves as an E3 ligase ligand-linker conjugate, utilizing a 5-Aminothalidomide-derived CRBN ligand. This compound is designed to facilitate the development of proteolysis-targeting chimeras (PROTACs), specifically enabling the synthesis of BT-O2C. Its application in protein regulation research underscores its potential in therapeutic strategies targeting E3 ligase-mediated degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 54 is a conjugate composed of Thalidomide and a specific linker, designed to target the E3 ligase Cereblon (CRBN). This compound facilitates the recruitment of CRBN, serving as a crucial intermediate in the development of PROTAC (Proteolysis Targeting Chimeras) molecules. E3 Ligase Ligand-Linker Conjugate 54 is valuable for research focused on targeted protein degradation and E3 ligase modulation, enhancing the understanding of cellular protein homeostasis. -
CRBN Ligand
Pomalidomide-5-C5-NH2 hydrochloride is a cereblon (CRBN) ligand derived from Pomalidomide, designed to facilitate the recruitment of the CRBN protein. This compound serves as a crucial component for the development of PROTACs that promote targeted protein degradation. Its unique structural modifications enhance its ability to engage with CRBN, enabling innovative research into therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-amide-pimelic acid serves as an E3 ligase ligand-linker conjugate, incorporating the Lenalidomide-derived CRBN ligand and a specialized linker. This compound is essential for the synthesis of PROTAC MNK1 degrader-1, facilitating targeted protein degradation via the ubiquitin-proteasome pathway. Its application enhances research into targeted therapies and the modulation of gene expression through protein degradation. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-7-bromohept-1-yne serves as an E3 ligase ligand-linker conjugate, facilitating the development of proteolysis-targeting chimeras (PROTACs). This compound is essential for targeted protein degradation research, allowing the selective modulation of protein levels in cellular systems. Its unique structure aids in enhancing therapeutic strategies by harnessing the ubiquitin-proteasome pathway for targeted degradation of specific proteins. -
E3 ligase ligand-linker conjugate
Pomalidomide-5'-C8-acid is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN) ligand derived from Pomalidomide. This compound is designed for use in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. Its unique structure allows for efficient engagement with E3 ligases, making it a valuable tool in molecular biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 34 is a compound that combines an E3 ligase ligand with a linker, specifically integrating Thalidomide to facilitate the recruitment of Cereblon (CRBN) proteins. This conjugate plays a crucial role in the development of PROTAC molecules, serving as an essential intermediate in targeted protein degradation research. Its applications are significant in studying E3 ligase-mediated ubiquitination and protein regulation pathways. -
Ligand for E3 Ligase
Pomalidomide-5-C9-NH2 hydrochloride is a potent ligand targeting the E3 ligase cereblon (CRBN). This compound facilitates the recruitment of CRBN protein, enabling targeted protein degradation. It serves as a valuable tool in the development of PROTACs (proteolysis-targeting chimeras) by linking with other ligands, thereby advancing research in cellular regulation and cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
JQ-1 carboxylic acid-PEG3-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for use in PROTAC (proteolysis-targeting chimera) synthesis. This compound facilitates targeted protein degradation by linking E3 ligases to proteins of interest, thereby enabling selective modulation of protein levels. It serves as a valuable tool in the investigation of protein regulation and therapeutic intervention strategies in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-C7-NH2 is an E3 ligase ligand-linker conjugate that facilitates the development of proteolysis-targeting chimeras (PROTACs). It serves as a crucial component for targeted protein degradation, enabling selective modulation of protein levels in various biological contexts. This compound is valuable for research applications in targeted therapy development and interrogation of cellular pathways involving E3 ligase interactions. -
Conjugate
(S,R,S)-AHPC-Me-CO-C9-NH2 is a versatile E3 ligase ligand utilized as a PROTAC linker. This conjugate enables the formation of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation in various cellular contexts. Its application in research is pivotal for studying protein interactions and developing novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-Linker Conjugate 183 is designed to target E3 ligases, facilitating the selective degradation of protein substrates through the ubiquitin-proteasome system. This conjugate features the LC3B ligand 2, which enhances autophagic degradation, and an optimized linker for effective delivery. Its applications include studies on protein turnover, cellular homeostasis, and targeted protein degradation, particularly in the context of PCSK9 regulation. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide 4'-alkylC3-acid is an E3 ligase ligand-linker conjugate that specifically engages the cereblon (CRBN) protein. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling targeted protein degradation. It is a valuable tool for researchers studying protein homeostasis and developing innovative therapeutic strategies in various disease models. -
CRBN Degrader-Linker Conjugate
CDLI-5 is a cereblon (CRBN) degrader-linker conjugate designed for the synthesis of cereblon degrader antibody conjugates (cDACs). This compound enables targeted protein degradation through the recruitment of E3 ligases to specific substrates, facilitating effective modulation of protein levels. CDLI-5 serves as a valuable tool in research applications focused on targeted therapies and the development of novel anticancer strategies.
